Humana Inc. $HUM Holdings Raised by Forsta AP Fonden

Forsta AP Fonden increased its position in shares of Humana Inc. (NYSE:HUM) by 2.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,900 shares of the insurance provider’s stock after purchasing an additional 700 shares during the period. Forsta AP Fonden’s holdings in Humana were worth $6,088,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of HUM. Vanguard Group Inc. lifted its stake in Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock valued at $3,697,222,000 after buying an additional 1,143,662 shares in the last quarter. Dodge & Cox increased its stake in shares of Humana by 5.5% in the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock worth $2,845,830,000 after acquiring an additional 557,175 shares during the last quarter. Pzena Investment Management LLC raised its holdings in shares of Humana by 6.5% during the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock worth $996,664,000 after acquiring an additional 247,744 shares in the last quarter. Davis Selected Advisers grew its stake in Humana by 3.3% in the first quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock valued at $616,873,000 after purchasing an additional 74,434 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC increased its position in Humana by 1.6% in the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider’s stock worth $327,293,000 after purchasing an additional 19,613 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Trading Up 0.1%

Shares of NYSE HUM opened at $236.94 on Friday. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The firm has a market capitalization of $28.50 billion, a P/E ratio of 18.18, a P/E/G ratio of 1.71 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The company’s 50 day simple moving average is $271.04 and its 200 day simple moving average is $258.05.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.29. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.65 billion during the quarter, compared to analysts’ expectations of $31.99 billion. During the same period in the previous year, the firm earned $4.16 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $3.54 annualized dividend and a yield of 1.5%. Humana’s dividend payout ratio (DPR) is presently 33.18%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on HUM shares. Wolfe Research boosted their target price on Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a report on Monday, October 6th. Piper Sandler lowered their price target on shares of Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a report on Thursday, July 31st. The Goldman Sachs Group initiated coverage on Humana in a research note on Tuesday, October 14th. They issued a “sell” rating and a $235.00 price target on the stock. Sanford C. Bernstein increased their target price on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, Mizuho lifted their target price on shares of Humana from $300.00 to $345.00 and gave the company an “outperform” rating in a research note on Thursday, October 9th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $298.39.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.